Guts & Glory: Both of Cynata’s iPSC Trials Flop, GVH Phase 2 and KOA Phase 3
Sad day for the industry, here's a summary of the CEO/Executive Chairman's readouts of the trials.
Category: Articles
Replacing Magnetic Separation with Buoyancy: A Closer Look at Bracco’s New Cell Selection Platform, BubbleGen™
Could a gentler, more scalable method improve how cells are isolated for advanced therapies? We spoke with Bracco’s Sophie He about the early data, manufacturing potential, and challenges ahead.
Interview: From Zero to One, How Terumo’s Ecosystem Blueprint Is Helping Scale Cell Therapies in Asia
Cell and gene therapies are advancing quickly, but the systems needed to deliver them at scale are still lagging behind. Terumo’s new Ecosystem Blueprint aims to bridge that gap in Asia-Pacific by...
Q&A – Inside iDEM, Mytos’ Automated Cell Therapy Manufacturing Platform
Pluripotent stem cell therapies are expensive, upwards of $500K–$1M per dose. Mytos has developed an automated manufacturing platform to bring that down, it's currently being used by many companies, including Aspen Neuroscience...
Interview: Veterinary Stem Cells – Gallant’s Quest for the First FDA-Approved MSC Therapy
Gallant is betting the future of veterinary regenerative medicine lies in scalable, well-characterized cell therapies. By sourcing mesenchymal stem cells from uterine tissue collected during routine spays, it has built an off-the-shelf...
Chinese Study Reports Intranasal Muse Stem Cells Show Potential for Parkinson’s Treatment
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a Parkinson’s mouse model.
Study Finds Bone Marrow-Derived Stem Cells No Better Than Placebo for Chronic Low Back Pain
The trial found no significant difference in pain or function outcomes between bone marrow injections and sham procedures over 12 months, but also had important limitations.
FDA’s New Regulatory Pathway May Forego RCTs for Ultra-Rare Conditions
Dr. Marty Makary and Dr. Vinay Prasad publish new article in New England Journal of Medicine, proposing a new pathway. Here are the details.
Interview: siRNA-Loaded Stem Cell Exosomes, Inside NurExone Biologic’s Spinal Cord Injury Candidate
NurExone's SCI candidate showed 100% gait recovery in rat models, and they're gearing up for human trials hopefully in 2026. Enjoy the interview!
Potential Retraction Coming on Pivotal Phase 3 Stem Cell Trial for Heart Failure
What appeared to be a potential stem cell breakthrough is slowly being torn apart by peer-reviewers, who found damning inconsistencies in the data.
